These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36662740)

  • 1. Real-life comparison of efficacy and safety profiles of two prolonged-release tacrolimus formulations in de novo kidney transplant recipients: 24 months of follow-up.
    Czarnecka P; Czarnecka K; Baczkowska T; Lagiewska B; Durlik M
    PLoS One; 2023; 18(1):e0278894. PubMed ID: 36662740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.
    Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L
    Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study.
    Bilbao I; Gómez Bravo MÁ; Otero A; Lladó L; Montero JL; González Dieguez L; Graus J; Pons Miñano JA
    Clin Transplant; 2023 Dec; 37(12):e15105. PubMed ID: 37615653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
    Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
    Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
    Fernandez Rivera C; Calvo Rodríguez M; Poveda JL; Pascual J; Crespo M; Gomez G; Cabello Pelegrin S; Paul J; Lauzurica R; Perez Mir M; Moreso F; Perelló M; Andres A; González E; Fernandez A; Mendiluce A; Fernández Carbajo B; Sanchez Fructuoso A; Calvo N; Suarez A; Bernal Blanco G; Osuna A; Ruiz-Fuentes MC; Melilli E; Montero Perez N; Ramos A; Fernández B; López V; Hernandez D;
    Clin Transplant; 2022 Mar; 36(3):e14550. PubMed ID: 34851532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advagraf® with or without an induction therapy for de novo kidney-transplant recipients.
    Noble J; Jouve T; Rostaing L; Malvezzi P
    Expert Rev Clin Immunol; 2018 Jun; 14(6):461-467. PubMed ID: 29757021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
    DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release tacrolimus dosing and outcomes in pediatric and young adult transplant recipients - A single-center experience.
    Huang X; Hapgood K; Allan K; Pruette C; Goswami E
    Pediatr Transplant; 2024 Feb; 28(1):e14611. PubMed ID: 37735900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus® versus Advagraf™ in liver transplant recipients.
    Wöhl DS; James B; Götz M; Brennfleck F; Holub-Hayles I; Mutzbauer I; Baccar S; Brunner SM; Geissler EK; Schlitt HJ;
    Trials; 2023 May; 24(1):325. PubMed ID: 37170284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Envarsus XR® pharmacokinetics in adolescents post-kidney transplantation - A pilot study.
    ElChaki R; Ettenger R; Lee S; Chen L; Gales B; Srivastava R; Pearl M
    Pediatr Transplant; 2023 May; 27(3):e14480. PubMed ID: 36732080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
    Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
    Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of LCP-Tacrolimus (Envarsus XR) in simultaneous pancreas and kidney (SPK) transplant recipients.
    Torabi J; Konicki A; Rocca JP; Ajaimy M; Campbell A; Azzi Y; Pynadath C; Liriano-Ward L; Akalin E; Kinkhabwala M; Graham JA
    Am J Surg; 2020 Apr; 219(4):583-586. PubMed ID: 32122660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial.
    Suwelack B; Bunnapradist S; Meier-Kriesche U; Stevens DR; Procaccianti C; Morganti R; Budde K
    Ann Transplant; 2020 Jul; 25():e923278. PubMed ID: 32719307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients.
    Jouve T; Rostaing L; Malvezzi P
    Expert Opin Drug Saf; 2017 Jul; 16(7):845-855. PubMed ID: 28494654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year outcomes of de novo tacrolimus extended-release tablets (LCPT) compared to twice-daily tacrolimus in adult heart transplantation.
    Alam A; van Zyl JS; Patel R; Jamil AK; Felius J; Carey SA; Gottlieb RL; Guerrero-Miranda CY; Kale P; Hall SA; Sam T
    Transpl Immunol; 2024 Apr; 83():102009. PubMed ID: 38325525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Switching From Immediate- or Prolonged-Release to Once-Daily Extended-Release Tacrolimus (LCPT) on Tremor in Stable Kidney Transplant Recipients: The Observational ELIT Study.
    Giral M; Grimbert P; Morin B; Bouvier N; Buchler M; Dantal J; Garrigue V; Bertrand D; Kamar N; Malvezzi P; Moreau K; Athea Y; Le Meur Y
    Transpl Int; 2024; 37():11571. PubMed ID: 38694490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial.
    Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S
    Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Effectiveness of Once-Daily, Prolonged-Release Tacrolimus in De Novo Kidney Transplant Recipients: 5-year, Multicenter Postmarketing Surveillance in Japan.
    Wakasugi N; Uchida H; Uno S
    Transplant Proc; 2018 Dec; 50(10):3296-3305. PubMed ID: 30577199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.